Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Recently published
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Blocking IL-10 receptor signaling ameliorates Mycobacterium tuberculosis infection during influenza-induced exacerbation
Sarah Ring, … , Gülsah Gabriel, Bianca E. Schneider
Sarah Ring, … , Gülsah Gabriel, Bianca E. Schneider
Published April 18, 2019
Citation Information: JCI Insight. 2019;4(10):e126533. https://doi.org/10.1172/jci.insight.126533.
View: Text | PDF
Research Article Immunology Infectious disease

Blocking IL-10 receptor signaling ameliorates Mycobacterium tuberculosis infection during influenza-induced exacerbation

  • Text
  • PDF
Abstract

Epidemiological findings indicate that coinfection with influenza viruses is associated with an increased risk of death in patients suffering from tuberculosis, but the underlying pathomechanisms are not well understood. In this study, we demonstrate that influenza A virus (IAV) coinfection rapidly impairs control of Mycobacterium tuberculosis (Mtb) in C57BL/6 mice. IAV coinfection was associated with significantly increased bacterial loads, reduced survival, and a substantial modulation of innate and adaptive immune defenses including an impaired onset and development of Mtb-specific CD4+ T cell responses and the accumulation of macrophages with increased arginase-1 production in the lungs. Our findings strongly indicate that IAV coinfection compromises the host’s ability to control Mtb infection via the production of IL-10, which was rapidly induced upon viral infection. The blockade of IL-10 receptor signaling reduced the bacterial load in coinfected mice to a level comparable to that in Mtb-only-infected animals. Taken together, our data suggest that IL-10 signaling constitutes a major pathway that enhances susceptibility to Mtb during concurrent IAV infection.

Authors

Sarah Ring, Lars Eggers, Jochen Behrends, Adam Wutkowski, Dominik Schwudke, Andrea Kröger, Alexandra Maximiliane Hierweger, Christoph Hölscher, Gülsah Gabriel, Bianca E. Schneider

×

Figure 2

Induction of antiviral immune responses and viral clearance are not impaired in the presence of Mtb.

Options: View larger image (or click on image) Download as PowerPoint
Induction of antiviral immune responses and viral clearance are not impa...
C57BL/6 mice were infected via aerosol with a low dose of Mtb H37Rv and 12 days later coinfected i.n. with 1 × 104 PFU IAV (A/HH/05/09 H1N1). Lungs collected at indicated time points were analyzed for (A) the activity of type I/III IFN and (B) Mx1 expression by qRT-PCR relative to Gapdh expression (n = 4 per group, representative of 2 independent experiments). (C) Shows total lung CD8+ T cell numbers and frequencies among CD45+ cells (n = 4 per group, representative of 2 independent experiments) and (D) H1N1-NP366 dextramer–specific CD8+ T cells (n = 5 per group, 1 experiment). (E) Viral titers were determined by MDCK plaque assay (n = 3–4 per group, representative of 4 (day 3 and day 6) and 2 (day 9) independent experiments). (A and B) Data are represented as mean + SD or (C–E) each point representing 1 mouse. *P ≤ 0.05; **P ≤ 0.01, ***P ≤ 0.001 determined by (A–D) 1-way ANOVA followed by Tukey’s multiple-comparison test and (E) unpaired t test.
Follow JCI Insight:
Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts